Barclays PLC lifted its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 1,316.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 140,113 shares of the company's stock after purchasing an additional 130,219 shares during the quarter. Barclays PLC's holdings in GoodRx were worth $973,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of GDRX. American Century Companies Inc. bought a new stake in shares of GoodRx during the 2nd quarter worth approximately $18,183,000. Point72 Asset Management L.P. purchased a new stake in GoodRx in the third quarter worth $11,295,000. Rubric Capital Management LP increased its stake in GoodRx by 76.5% in the second quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company's stock worth $29,147,000 after purchasing an additional 1,619,748 shares during the period. Millennium Management LLC lifted its position in shares of GoodRx by 36.5% during the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company's stock worth $32,151,000 after purchasing an additional 1,102,758 shares during the last quarter. Finally, Pier Capital LLC purchased a new stake in shares of GoodRx during the third quarter valued at $3,259,000. Institutional investors own 63.77% of the company's stock.
GoodRx Stock Up 4.8 %
Shares of NASDAQ:GDRX traded up $0.20 during trading on Wednesday, reaching $4.35. The stock had a trading volume of 1,237,916 shares, compared to its average volume of 1,365,432. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $1.66 billion, a P/E ratio of -145.00, a PEG ratio of 3.43 and a beta of 1.27. The firm's 50-day simple moving average is $4.65 and its 200 day simple moving average is $6.50. GoodRx Holdings, Inc. has a one year low of $4.09 and a one year high of $9.26.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the stock. Mizuho initiated coverage on shares of GoodRx in a report on Wednesday, December 4th. They set a "neutral" rating and a $5.00 price objective for the company. Citigroup reduced their target price on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research report on Friday, January 10th. KeyCorp lowered their price target on GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Barclays reduced their price objective on GoodRx from $10.00 to $6.00 and set an "overweight" rating on the stock in a report on Monday, November 11th. Finally, Morgan Stanley lowered their target price on GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Five equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, GoodRx presently has an average rating of "Moderate Buy" and a consensus target price of $8.38.
Read Our Latest Stock Report on GDRX
GoodRx Profile
(
Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Further Reading
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.